Preliminary analysis of therapeutic efficacy and prognosis of allogeneic hematopoietic stem cell transplantation in patients with advanced chronic myeloid leukemia.
- Author:
A-Xia SONG
1
;
Dong-Lin YANG
;
Jia-Lin WEI
;
Zhang-Song YAN
;
Mei WANG
;
Er-Lie JIANG
;
Yong HUANG
;
Qiao-Ling MA
;
Yi HE
;
Wei-Hua ZHAI
;
Rong-Li ZHANG
;
Si-Zhou FENG
;
Ming-Zhe HAN
Author Information
1. Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin 300020, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Benzamides;
Child;
Child, Preschool;
Female;
Hematopoietic Stem Cell Transplantation;
methods;
Humans;
Imatinib Mesylate;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
drug therapy;
surgery;
therapy;
Male;
Middle Aged;
Piperazines;
therapeutic use;
Prognosis;
Pyrimidines;
therapeutic use;
Retrospective Studies;
Young Adult
- From:
Journal of Experimental Hematology
2011;19(1):149-153
- CountryChina
- Language:Chinese
-
Abstract:
Chronic myeloid leukemia (CML) at advanced and blastic phase is a disease with poor prognosis, for which allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment choice with curative potential. This study was purposed to investigate the therapeutic efficacy of allo-HSCT and prognosis of advanced CML patients. The 28 cases of CML in accelerated phase or blast crisis received allo-HSCT were analysed retrospectively in terms curative efficacy, basic characteristics before transplant and prognosis, therapeutic strategy before transplant and prognosis, events after transplant and prognosis. The results indicated that 10 out of 28 patients were in complete remission, showing a 3-year overall survival and disease-free survival rate of 34.9% and 35.7% respectively; 18 patients died. Univariate analysis revealed that the clonal evolution and blast amount are baseline risk factor of poor prognosis, and combination of them can be used to predict the outcome of patients; application of imatinib before transplant and achievement of complete hematologic remission could not improve the prognosis; severe aGVHD among post-transplant events was proven to be a negative prognostic factor. It is concluded that for advanced CML patients received allo-HSCT, clonal evolution and blast percentage are prognostic factors, and the pre-transplant use of imatinib did not influence the outcome.
